Open AccessThe Joint United Nations Programme on HIV/AIDS 95–95–95 targets: worldwide clinical and cost benefits of generic manufacture
Author(s) -
Katherine Heath,
Jacob Levi,
Andrew Hill
Publication year - 2021
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/qad.0000000000002983
Subject(s) - medicine , developing country , environmental health , human immunodeficiency virus (hiv) , epidemiology , global health , public health , demography , family medicine , economic growth , economics , nursing , sociology
The Joint United Nations Programme on HIV/AIDS aims for HIV testing, treatment and viral suppression rates to be 95%--95%--95% by 2025. Patented drug prices remain a barrier to HIV treatment. Generic alternatives are being produced and exported from countries without patent barriers at a fraction of the cost.